Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Bimetallic ZIF nanoplatform for pH-responsive curcumin delivery: synthesis, characterization, and in vitro evaluation.

Created on 20 Oct 2026

Authors

Luan Minh Nguyen, Giao Thuy Quynh Vu, Tan Phat Nguyen, Manh Hoang Tran, Thi My Huyen Nguyen, Long Binh Vong, Dai Hai Nguyen

Published in

RSC advances. Oct 19, 2026. Epub Oct 19, 2026.

Abstract

The exploration of zeolitic imidazolate framework (ZIF)-based nanoplatforms for drug delivery has attracted increasing attention in recent years. In this study, a bimetallic ZIF (BZIF) containing Zn and Co was synthesized through a simple one-pot approach under mild conditions. The formation of BZIF was confirmed through comprehensive physicochemical characterization. Curcumin (CUR) was subsequently loaded onto BZIF to obtain the CBZIF nanoplatform. CBZIF exhibited pH-responsive CUR release, with cumulative release reaching 78.19% at pH 5.5 compared with 44.25% at pH 7.4 after 72 h. In vitro studies demonstrated that CBZIF maintained favorable biocompatibility toward normal L929 cells while exhibiting enhanced anticancer activity against C26 cancer cells compared with free CUR and pristine BZIF. Overall, these findings suggest that CBZIF is a promising nanoplatform for pH-responsive CUR delivery and provide a basis for further investigation of its potential biomedical applications.

PMID:
42898706
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement